首页> 美国卫生研究院文献>International Journal of Medical Sciences >Cyclic Phosphatidic Acid Inhibits Alkyl-Glycerophosphate-Induced Downregulation of Histone Deacetylase 2 Expression and Suppresses the Inflammatory Response in Human Coronary Artery Endothelial Cells
【2h】

Cyclic Phosphatidic Acid Inhibits Alkyl-Glycerophosphate-Induced Downregulation of Histone Deacetylase 2 Expression and Suppresses the Inflammatory Response in Human Coronary Artery Endothelial Cells

机译:环磷酸抑制烷基甘油磷酸诱导的组蛋白脱乙酰基酶2表达下调并抑制人冠状动脉内皮细胞的炎症反应。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Activation of the endothelium by alkyl-glycerophosphate (AGP) has been implicated in the development of atherosclerosis. Our previous study suggested that cyclic phosphatidic acid (cPA) inhibits arterial wall remodeling in a rat model in vivo. However, the mechanisms through which specific target genes are regulated during this process remain unclear. Here, we examined whether cPA inhibited AGP-induced expression of class I histone deacetylases (HDACs, namely HDAC1, HDAC2, HDAC3, and HDAC8), which may affect subsequent transcriptional activity of target genes. Our experimental results showed that human coronary artery endothelial cells (HCAECs) expressed high levels of HDAC2 and low levels HDAC1, HDAC3, and HDAC8. Moreover, AGP treatment induced downregulation of HDAC2 expression in HCAECs. However, cotreatment with cPA inhibited this downregulation of HDAC2 expression. Interestingly, treatment with AGP increased the expression and secretion of endogenous interleukin (IL)-6 and IL-8; however, this effect was inhibited when HCAECs were cotreated with cPA or the synthetic peroxisome proliferator-activator receptor gamma (PPARγ) antagonist T0070907. Thus, our data suggested that cPA may have beneficial effects in inflammation-related cardiovascular disease by controlling HDAC2 regulation.
机译:烷基甘油磷酸酯(AGP)对内皮的激活与动脉粥样硬化的发展有关。我们以前的研究表明,在大鼠体内,环状磷脂酸(cPA)会抑制动脉壁重塑。但是,在此过程中调控特定靶基因的机制尚不清楚。在这里,我们检查了cPA是否抑制AGP诱导的I类组蛋白脱乙酰基酶(HDAC,即HDAC1,HDAC2,HDAC3和HDAC8)的表达,这可能会影响随后的靶基因转录活性。我们的实验结果表明,人冠状动脉内皮细胞(HCAEC)表达高水平的HDAC2和低水平的HDAC1,HDAC3和HDAC8。此外,AGP处理诱导了HCAECs中HDAC2表达的下调。但是,与cPA共同处理抑制了HDAC2表达的这种下调。有趣的是,用AGP治疗可增加内源性白介素(IL)-6和IL-8的表达和分泌。但是,当将HCAEC与cPA或合成的过氧化物酶体增殖物-激活物受体伽玛(PPARγ)拮抗剂T0070907共同治疗时,该作用被抑制。因此,我们的数据表明,cPA可能通过控制HDAC2调节而对炎症相关的心血管疾病产生有益的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号